Kornimate/medical-research-clean huggingface dataset:
nicotinic enhancement of cognitive remediation training in schizophrenia

Conditions: Schizophrenia; Schizoaffective Disorder

Summary: schizophrenia is marked by problems in attention, memory and problem solving. these deficits predict long-term functional outcome such as the ability to live independently and maintain employment, but they are not ameliorated by currently available medications. cognitive training improves these functions to some degree, but this approach is time- and resource-intensive. the current project aims at enhancing and accelerating the benefits that people with schizophrenia derive from cognitive training by administering nicotine during some of the training sessions. this would provide the proof of principle for a type of treatment intervention to improve cognitive symptoms of schizophrenia. the current project aims at determining whether the intermittent presence of nicotine during cognitive training exercises in people with schizophrenia will shorten the training period necessary to induce significant and clinically relevant improvement and enhance the improvement seen after a training period of specified length. hypothesis 1a: nicotine administration during training will increase the size of all measured effects of the training intervention, and will accelerate the time course of performance enhancement on the mccb and training exercise progression parameters. hypothesis 1b: the larger training effects in the nicotine group will persist beyond the end of the intervention. hypothesis 2a: within-session progress on the training exercises will be larger in the presence of nicotine than in the presence of placebo. hypothesis 2b: these acute nicotine-induced performance elevations will persist beyond the presence of nicotine through subsequent non-drug training sessions, giving evidence of an acute facilitation of learning processes.


Eligibility criteria:
inclusion criteria: * aged 18-60 years. * dsm diagnosis of schizophrenia or schizoaffective disorder. * ability to give written informed consent. * either currently smoking and not attempting to quit, or having smoked no more than 80 cigarettes, cigarillos or cigars in lifetime and not at all within the last year. * normal or corrected to normal vision (at least 20/50). * four weeks of stable pharmacological treatment (same psychiatric medication at same dose) and no foreseeable changes at enrollment. exclusion criteria: * alcohol or substance abuse or dependence other than nicotine within the last 12 months. * uncontrolled hypertension (resting systolic blood pressure above 150 or diastolic above 90 mm hg). * history of myocardial infarction, heart failure, angina, stroke or severe arrhythmias. * ecg abnormalities. * history of neurological conditions such as stroke, seizures, dementia or organic brain syndrome. * mental retardation. * pregnant, verified by urine pregnancy test for females. * breast-feeding. * treated with benztropine currently or within the last four weeks.

Keywords: schizophrenia cognition cognitive remediation nicotine
neuropsychological evaluation of psychiatric and neurological patients

Conditions: Anxiety Disorder; Head Injury; Mood Disorder; Schizophrenia; Seizures

Summary: this study will allow researchers to use various types of tests to evaluate cognitive and sensory functions. these tests, referred to as "batteries" will evaluate attention, executive functions, general intellectual functioning, language, memory, motor functions, orientation, personality, selected sensory and perceptual functions, vigilance (alertness), and visual-spatial functions. children and adult patient will receive different test batteries. the goals of this research study are to; 1. create descriptions based on the performance of each patient on the test batteries. then use this information to relate patient behavior to their neurophysiological, neuroradiological, and biochemical descriptions. 2. define subgroups of patients based on their neurobehavior in order to decrease the variability of psychiatric diagnoses, treatments, and prognoses.

neuropsychological tests are used to provide an assessment of cognitive functions in patients with idiopathic generalized epileptic (ige) disorders and their first-degree relatives. the battery comprises tests designed to tap attention, memory, selected sensory and perceptual functions, vigilance, and visual-spatial functions. modified batteries have been developed for the assessment of children ages 5-8, and children ages 8-16. the data provided by these batteries are compared with genetic profiles of the same participants that have been ascertained from blood samples analyzed by colleagues at the mount sinai school of medicine/columbia university in new york city.

Eligibility criteria:
* inclusion criteria: patients. normal volunteers. exclusion criteria: subjects over 95 years of age. subjects with a history of alcohol or drug abuse, psychopathology, or central nervous system pathology, other than that which defines group membership, may be excluded.

Keywords: executive functions language attention visual-spatial ability memory motor behavior intelligence personality visual and auditory functioning hand and eye dominance normal volunteer neuropsychiatric disorders
olanzapine plus carbamazepine in the treatment of bipolar i mania

Conditions: Bipolar Disorder

Summary: this trial will assess any efficacious benefit and any safety issues associated with the concomitant use of olanzapine and carbamazepine for the treatment of patients with bipolar i disorder, manic or mixed episodes


Eligibility criteria:
inclusion criteria: 1. have a diagnosis of bipolar disorder and currently meet dsm-iv-tr criteria for a manic or mixed episode 2. female patients must test negative on a serum pregnancy test at the time of enrollment and agree to use medically accepted contraception throughout the study. 3. have ymrs score \> or = 20 at both the screening (visit 1) and randomization (visit 2) visits. exclusion criteria: 1. have participated (been randomized) in a clinical trial of another investigational drug (including olanzapine or carbamazepine) within 30 days prior to visit 1 2. have a history of agranulocytosis (absolute neutrophil count\< 500/ul) during the patient's lifetime 3. have acute, serious or unstable medical conditions, including (but not limited to) inadequately controlled diabetes (hgba1c\>8%); severe hypertriglyceridemia (fasting triglycerides \> or = 500 mg/dl;hepatic insufficiency (specifically any degree of jaundice); recent cerebrovascular accidents; uncontrolled seizure disorders; serious acute systemic infection or immunologic disease: unstable cardiovascular disorders (including ischemic heart disease); or renal, gastroenterologic, respiratory, endocrinologic, neurologic, or hematologic diseases (specifically current absolute neutrophil count , \<1500/ul) 4. have a substance dependence (except nicotine or caffeine), based on dsm-iv-tr criteria, within the 30 days prior to study entry. 5. require concomitant treatment with any other medication with primarily central nervous system (cns) activity, other than those allowed in the protocol.
vitamin a status in patients with vocal fold leukoplakia

Conditions: Vitamin A; Vitamin A Deficiency; Leukoplakia; Vocal Cord Neoplasm

Summary: this study will determine systemic vitamin a status and lesion histopathology of participants with vocal fold hyperkeratosis resulting in clinical leukoplakia.

the investigator's overarching goal is to determine if there is a pathophysiologic rationale for vitamin a supplementation in the treatment of vocal fold hyperkeratosis. vocal fold hyperkeratosis is an accumulation of epithelial surface keratin resulting in clinical leukoplakia. it is primarily managed using destructive techniques that risk iatrogenic injury, fibrosis, and voice impairment. given the potential morbidity of biopsy and lesion removal, there is a need for new approaches to the prevention and treatment of vocal fold leukoplakic disorders that are non-destructive. vitamin a is a key regulator of epithelial health and systemic vitamin a deficiency could directly contribute to hyperkeratosis. based on vitamin a's importance to vocal fold stellate and epithelial cell biology and its direct relevance to vocal fold hyperkeratosis, this study will assess vitamin a status in participants with vocal fold hyperkeratosis. an association would suggest further study on the effects of vitamin a optimization and/or supplementation in patients with leukoplakia, as well as an adjuvant therapy in participants for whom surgical treatment is indicated.

Eligibility criteria:
inclusion criteria: 1. willing to provide informed consent. 2. willing to comply with all study procedures and be available for the duration of the study. 3. ability to take oral medication. 4. at least 18 years of age. 5. leukoplakia study groups: 1. leukoplakia due to hyperkeratosis with dysplasia: biopsy-confirmed diagnosis of hyperkeratosis with dysplasia. 2. leukoplakia due to hyperkeratosis with no dysplasia: biopsy-confirmed diagnosis of hyperkeratosis with no dysplasia. 6. control group: laryngoscopy showing no evidence of vocal fold epithelial disease. exclusion criteria: 1. history of malignant vocal fold epithelial pathology. 2. history of metabolic or liver disorder. 3. history of anorexia or bulimia. 4. pregnant, lactating, or planning on becoming pregnant during the study period. 5. history of \>4.5 kg weight loss in the past 90 days. 6. medical or other inability to complete an 8 hour fast. 7. acute respiratory or gastrointestinal illness. 8. currently incarcerated. 9. impaired decision-making capacity. 10. no or limited english speaking ability; illiterate or low-literacy ability. 11. profound visual or hearing impairment that limits written or verbal communication. 12. status relationship with a member of the study team. 13. not suitable for study participation due to other reasons at the discretion of the investigators.
normothermia in patients with acute cerebral damage

Conditions: Traumatic Brain Injury; Subarachnoid Hemorrhage

Summary: the purpose of our study is to verify wherever normothermia (achieved with diclofenac administration) may improve intracranial pressure control and may limit secondary cerebral damage thus positively influencing outcome in patients with acute cerebral damage admitted to icu.

pyrexia can exacerbate ischemic neuronal damage and physiological dysfunction after traumatic brain injury and subarachnoid hemorrhage.fever also represent an important issue occurring in 78% of patients with acute cerebral damage admitted to intensive care unit (icu). for those patients, normothermia is actually recommended in order to reduce secondary cerebral damage and to control intracranial pressure, that are known to worsen long term prognosis. our primary endpoint is to maintain normothermia in patients with acute cerebral damage (axillary temperature \< 38°c or internal temperature \< 38,8°c) administering diclofenac. we will also investigate the corresponding behaviour of intracranial pressure and cerebral perfusion pressure. comparison(s): we will compare two different doses of subcutaneous diclofenac (0,35 mg/kg - 1/3 a vial - vs 0,5 mg/kg - 1/2 vial) to continuous intravenous of 0,48 mg/kg diclofenac for 12 hours.

Eligibility criteria:
inclusion criteria: * patients with severe traumatic injury or subarachnoid hemorrhage in coma (gcs\<8), intubated, mechanically ventilated with intracranial pressure (icp) and invasive arterial pressure monitoring exclusion criteria: * know adverse reactions with nsai * platelets count \< 20,000/dl * gastric or duodenal ulceration in active phase * hepatic insufficiency, cirrhosis or previous liver transplant * acute or chronic renal insufficiency * coronary insufficiency, acute myocardial infarct in the previous 6 month * barbiturate coma * patients in therapy with acetylsalicylic acid, lithium, digoxin, methotrexate and cyclosporin. * known or suspected pregnancy

Keywords: fever acute cerebral damage normothermia diclofenac icu outcome intracranial pressure cerebral perfusion pressure traumatic brain injury subarachnoid hemorrhage
technical feasibility study of ultrasound muscle imaging in antenatal ultrasound

Conditions: Arthrogryposis Multiplex Congenita (AMC)

Summary: the objective of the study is to evaluate the performance of muscle ultrasound sections on antenatal ultrasound between 21-24 amenorrhea weeks for the screening of muscle atrophy, in a sample of low-risk and high-risk pregnancies of congenital multiple arthrogryposis

frequent rare diseases (100-200 births in france / year), congenital multiple arthrogryposis include a set of pathologies characterized by the limitation of joint movements at least two joint levels.their functional prognosis and muscle atrophy are often severe after birth. routine ultrasound call signs are either non-specific or insensitive and difficult to detect due to time constraints. antenatal ultrasound screening is not very effective for these pathologies, which are often particularly serious. the main criterion will be the success rate of realization of all four ultrasound sections at the extremities (deltoide, biceps, quadriceps, triceps) and measurements of the distances "skin - muscle fascia" and "muscular fascia - periosteum" between 21-24 amenorrhea weeks

Eligibility criteria:
inclusion criteria: * any pregnant woman consulting in one of the two obstetric gynecology departments in connection with the cpdpn (multidisciplinary prenatal diagnostic centers) of the university hospitals of lyon or grenoble. * mono-embryonic pregnancy. * gestational ages retained on the first dating ultrasound or the 1st trimester ultrasound between 21-24 amenorrhea weeks. * for women at "high risk": diagnosis during ultrasound of the 1st, 2nd, or 3rd trimesters, of an abnormality of position / deformation of one or more joints, and / or an abnormality of fetal movements on screening ultrasound or interrogation (population group at "high risk of amc"). * regulatory criteria: adults, affiliated to a social security scheme, having signed a consent exclusion criteria: * multiple pregnancies, and / or non-progressive . * obese women (bmi \> 30 in early pregnancy) * subject in a period of exclusion from another study * subject under administrative or judicial supervision * subject who cannot be contacted in case of emergency
physical activity intervention for young cancer survivors

Conditions: Breast Cancer; Quality of Life; Physical Activity

Summary: the proposed mixed methods pilot study will enroll 20 young breast cancer survivors into a 12-week technology-based, remotely-delivered, peer-moderated physical activity program to examine the effects of the intervention on objectively measured physical activity and multiple aspects of quality of life; and conduct qualitative analyses to refine the intervention for a future randomized controlled trial.

young breast cancer survivors (i.e. those \< 50 years old) have lower survival rates than their older counterparts and experience unique physical and mental challenges associated with their cancer treatments. depression, anxiety, and poor body image are common in young breast cancer survivors. research in older breast cancer survivors has shown that physical activity can decrease cancer recurrence and mortality, and improve many aspects of quality of life. few physical activity intervention studies have been conducted in young breast cancer survivors, despite the fact that young survivors would be best served by age-specific interventions designed to target their needs. remotely-delivered, technology-based interventions may be important to help young breast cancer survivors overcome unique barriers to increasing physical activity and improving quality of life. the study aims are: 1) explore the feasibility and acceptability of a technology-based, remotely-delivered, peer-moderated physical activity intervention for young breast cancer survivors; 2a) assess the invention's impact on change in physical activity; and 2b) measure the intervention's effect on multiple aspects of quality of life

Eligibility criteria:
inclusion criteria: * diagnosed with breast cancer between 18-49 years old * completed active treatment (chemotherapy, radiation) at least 6 months prior to enrollment * self-report low levels of moderate to vigorous physical activity each week * accessible by phone or video chat * have a fitbit compatible cellphone, tablet, or laptop with internet exclusion criteria: * medical condition that could make it potentially unsafe to be in an unsupervised physical activity intervention * currently pregnant * unable to commit to intervention schedule * prisoner
progress bifurcation global registry

Conditions: Coronary Artery Disease; Coronary Bifurcation Lesions

Summary: coronary bifurcation lesions are lesions (or blockages) that occur at or near the intersection of a major coronary artery and one of the arteries' side branches. numerous techniques and devices have been developed to treat coronary bifurcations; however, these types of lesions remain some of the most challenging, both in terms of procedural success and outcome. this study is designed as an observational, multi-center registry that will collect information on treatment strategies and outcomes of consecutive patients undergoing percutaneous coronary interventions (pci) in coronary bifurcations among various participating centers, in order to determine the frequency of bifurcation pci, the procedural strategies utilized, and the procedural outcomes.

numerous techniques and devices have been developed to treat coronary bifurcations; however, these types of lesions remain some of the most challenging, both in terms of procedural success and outcome. several techniques are currently being utilized to treat coronary bifurcation lesions, including a 1-stent provisional stenting technique. various 2-stent techniques are also performed, including: double kiss crush (dk crush4), culotte, t and protrusion (tap), crush, mini-crush, reverse crush and v-stenting. the optimal technique for bifurcation stenting when two stents are required remains controversial; however, the dk crush technique appears to have stronger data, especially for left main bifurcations. however, dk crush can be challenging to perform, requiring several steps and frequent troubleshooting. the adoption of dk crush and other 2-stent bifurcation strategies, as well as the rigor of implementation, have received limited study. this study is designed as an observational, multi-center registry that will collect information on treatment strategies and outcomes of consecutive patients undergoing percutaneous coronary interventions (pci) in coronary bifurcations among various participating centers, in order to determine the frequency of bifurcation pci, the procedural strategies utilized,

Eligibility criteria:
inclusion criteria: * over 18 years of age * undergoing bifurcation percutaneous coronary intervention

Keywords: bifurcation lesions percutaneous coronary intervention
an observational study of patients with chronic kidney disease

Conditions: Kidney Disease, Chronic; End Stage Kidney Disease

Summary: target-kidney is an observational research study to conduct a comprehensive review of outcomes for patients with chronic kidney disease (ckd) and end-stage renal disease (eskd).


Eligibility criteria:
disease cohort inclusion criteria: * adult\* patients at the time of enrollment with a diagnosis of ckd/eskd by icd-10 code in the ehr interface exclusion criteria: * death * manual removal (sponsor or site request) * no ehr interface encounter \> 3 years engaged cohort inclusion criteria: * adult \* patients diagnosed and managed for ckd/eskd invited to participate * ability to provide written informed consent exclusion criteria: * patient expressed desire to withdraw consent to complete pros * failure to complete pros within 24 weeks of initial invitation * greater than 24 months lapse of survey completion after baseline surveys completed * additionally, the criteria detailed for disease cohort apply to the engaged cohort
optimizing cardiac resynchronization

Conditions: Heart Failure

Summary: cardiac resynchronization therapy shows great promise as a method to improve ventricular function in heart failure due to dilated cardiomyopathy. it is applied to patients with class iii and iv symptomatic heart failure on optimal therapy. typical entry criteria in the trials testing resynchronization have used the electrocardiogram and a prolonged electrocardiogram (ecg) qrs interval as criteria for dyssynchrony. this is recognized to be quite limited as a tool for identifying patients. several new echocardiographic methods for identifying dyssynchrony have been proposed. the purpose of this study is to systematically examine these multiple echocardiographic measurement techniques in three conditions: 1. in the patient's native rhythm simulated by changing the pacing system to atrial pacing only; 2. in conventional dual chamber pacing (ddd mode); and 3. during biventricular pacing. all patients entered into this study will already have had a biventricular pacemaker placed.


Eligibility criteria:
inclusion criteria: * all patients who have previously had a resynchronization pacemaker system placed at the university of wisconsin hospital or at the middleton veterans hospital are potentially eligible for this study. * the study is only open to patients as enumerated above, and also patients who have good imaging windows.

Keywords: heart failure cardiac resynchronization echocardiography
characterisation of dengue vaccine-induced specific immunity in vaccinees with and without prior exposure to flavivirus infections or vaccination

Conditions: Dengue Vaccines

Summary: the goal of this observational study is to learn about the immunity induced by the qdenga® vaccine in vaccinees. participants that will receive the dengue vaccine as part of their routine before a travel will be asked to undergo a blood sample at the time of administration of the first dose (t0), 24-48 hours after the first dose (t1) of the vaccine, immediately before the second dose (t2 ) and one to two months after the second dose (t3). possibly a further sample will be collected within 2 years.

this is a non-profit, single-center, drug-based observational study whose primary objective is to characterize dengue-specific humoral and cellular immunity induced by the qdenga® vaccine in vaccinees. the study involves the enrollment of all pediatric subjects (age ≥ 4 years) and adults who present themselves at the ditm travel clinic for the administration of the dengue vaccine; 402 patients are expected to be enrolled and will be asked to undergo a blood sample at the time of administration of the first dose (t0), 24-48 hours after the first dose (t1) of the vaccine, immediately before the second dose (t2 ) and one to two months after the second dose (t3). possibly a further sample will be collected within 2 years (t4). the samples thus collected will be analyzed for the characterization of innate immunity, the characterization of cellular immunity and the characterization of the humoral response.

Eligibility criteria:
inclusion criteria: * subjects of both sexes presenting to the ditm to receive the anti-denv vaccine whether or not they have had a history of prior denv or other flaviviruses infection or a history of prior vaccination against other flaviviruses. these data will be recorded in the study crf. * age \>= 4 years. * signed informed consent. exclusion criteria: * age \< 4 years. * absence of signed informed consent.

Keywords: dengue vaccine